סולפמתופרים פרמיקס וטרינרי ישראל - עברית - Ministry of Health

סולפמתופרים פרמיקס וטרינרי

abic veterinary products ltd - sulphadiazine; trimethoprim - אבקה - sulphadiazine 250 mg/g; trimethoprim 50 mg/g

קוקסידין יובפרמה 200   וטרינרי ישראל - עברית - Ministry of Health

קוקסידין יובפרמה 200 וטרינרי

g.w. oracel internat. ltd - monensin sodium - אבקה - monensin sodium 200 g/kg

גלוקומין ישראל - עברית - Ministry of Health

גלוקומין

dexcel ltd, israel - metformin hydrochloride - קפליות - metformin hydrochloride 850 mg - metformin - metformin - treatment of non-insulin diabetes mellitus not responding to dietary modification.

אקרוז 50 ישראל - עברית - Ministry of Health

אקרוז 50

rafa laboratories ltd - acarbose - טבליה - acarbose 50 mg - acarbose - acarbose - treatment of non-insulin dependent diabetes mellitus (niddm) in patients inadequately controlled on diet alone, or on diet and oral hypoglycaemic agents.

אקרוז 100 ישראל - עברית - Ministry of Health

אקרוז 100

rafa laboratories ltd - acarbose - טבליה - acarbose 100 mg - acarbose - acarbose - treatment of non-insulin dependent diabetes mellitus (niddm) in patients inadequately controlled on diet alone, or on diet and oral hypoglycaemic agents.

סומאברט 10 מג ישראל - עברית - Ministry of Health

סומאברט 10 מג

pfizer pharmaceuticals israel ltd - pegvisomant - אבקה וממס להכנת תמיסה להזרקה - pegvisomant 10 mg - pegvisomant - pegvisomant - treatment of patient with acromegaly who have had an inadequate response to surgery and/or radiation therapy and in whom an appropriate medical treatment with somatostatin analogues did not normalize igf-i concentrations or was not tolerated.

סומאברט 15 מג ישראל - עברית - Ministry of Health

סומאברט 15 מג

pfizer pharmaceuticals israel ltd - pegvisomant - אבקה וממס להכנת תמיסה להזרקה - pegvisomant 15 mg - pegvisomant - pegvisomant - treatment of patient with acromegaly who have had an inadequate response to surgery and/or radiation therapy and in whom an appropriate medical treatment with somatostatin analogues did not narmalize igf-i concentrations or was not tolerated.

סומאברט 20 מג ישראל - עברית - Ministry of Health

סומאברט 20 מג

pfizer pharmaceuticals israel ltd - pegvisomant - אבקה וממס להכנת תמיסה להזרקה - pegvisomant 20 mg - pegvisomant - pegvisomant - treatment of patient with acromegaly who have had an inadequate response to surgery and/or radiation therapy and in whom an appropriate medical treatment with somatostatin analogues did not narmalize igf-i concentrations or was not tolerated.

סנדוסטטין   0.1 מגמל ישראל - עברית - Ministry of Health

סנדוסטטין 0.1 מגמל

novartis israel ltd - octreotide - תמיסה להזרקה\אינפוזיה - octreotide 0.1 mg/ml - octreotide - octreotide - prevention of complications following pancreatic surgery. symptomatic control and reduction of gh and igf-1plasma levels in patients with acromegaly who are inadequately controlled by surgery or radiotherapy. sandostatin treatment is also indicated for acromegalic patients unfit or unwilling to undergo surgery or in the interim period until radiotherapy becomes fully effective. relief of symptoms associated with functional gastroenteropancreatic endocrine tumours: - carcinoid tumours with features of the carcinoid syndrome - vipomas - glucagonomas - gastrinomas / zollinger-ellison syndrome usually in conjunction with proton pump inhibitors or h2- antagonist therapy - insulinomas for pre-operative control of hypoglycaemia and for maintenance therapy - grfomas. sandostatin is not an antitumour therapy and is not curative in these patients.emergency management of bleeding gastro-oesophageal varices secondary to cirrhosis in combination with specific therapy such as endoscopic sclerotherapy.

סנדוסטטין   0.2 מגמל ישראל - עברית - Ministry of Health

סנדוסטטין 0.2 מגמל

novartis israel ltd - octreotide - תמיסה להזרקה\אינפוזיה - octreotide 0.2 mg/ml - octreotide - octreotide - prevention of complications following pancreatic surgery. symptomatic control and reduction of gh and igf-1plasma levels in patients with acromegaly who are inadequately controlled by surgery or radiotherapy. sandostatin treatment is also indicated for acromegalic patients unfit or unwilling to undergo surgery or in the interim period until radiotherapy becomes fully effective. relief of symptoms associated with functional gastroenteropancreatic endocrine tumours: - carcinoid tumours with features of the carcinoid syndrome - vipomas - glucagonomas - gastrinomas / zollinger-ellison syndrome usually in conjunction with proton pump inhibitors or h2- antagonist therapy - insulinomas for pre-operative control of hypoglycaemia and for maintenance therapy - grfomas. sandostatin is not an antitumour therapy and is not curative in these patients.emergency management of bleeding gastro-oesophageal varices secondary to cirrhosis in combination with specific therapy such as endoscopic sclerotherapy.